Mirae Asset Global Investments Co. Ltd. Raises Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Mirae Asset Global Investments Co. Ltd. lifted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 9.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,570 shares of the biotechnology company’s stock after purchasing an additional 568 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Sarepta Therapeutics were worth $797,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after buying an additional 156 shares during the period. Sunbelt Securities Inc. raised its holdings in shares of Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 232 shares in the last quarter. Huntington National Bank lifted its stake in Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 175 shares during the period. UMB Bank n.a. grew its holdings in Sarepta Therapeutics by 105.9% during the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 197 shares in the last quarter. Finally, Values First Advisors Inc. bought a new stake in shares of Sarepta Therapeutics in the 3rd quarter valued at about $59,000. Institutional investors own 86.68% of the company’s stock.

Insiders Place Their Bets

In related news, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares of the company’s stock, valued at approximately $738,234. This represents a 21.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares in the company, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Analyst Upgrades and Downgrades

SRPT has been the topic of a number of recent research reports. Needham & Company LLC reiterated a “buy” rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, January 27th. Evercore ISI dropped their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Guggenheim boosted their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. Finally, Robert W. Baird reduced their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $176.77.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $109.68 on Wednesday. Sarepta Therapeutics, Inc. has a 52-week low of $102.15 and a 52-week high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The stock has a market cap of $10.48 billion, a PE ratio of 87.74 and a beta of 0.75. The business has a 50-day simple moving average of $120.49 and a 200-day simple moving average of $125.33.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.